Use of pentadienoic acid derivatives for the treatment of hyperuricemia

A method for preventing or treating hyperuricemia;

• or for treating a disorder associated with hyperuricemia;
• or for reducing the serum uric acid level of a subject, comprising administering to a subject in need thereof a compound of formula (I)
• in which:
• X is O or S;
• A is a divalent radical —(CH2)s—CO—(CH2)t— or —(CH2)s—CR3R4—(CH12)t—, in which s=t=0 or one of s and t has the value 0 and the other has the value 1;
• R1 and R2 are, each independently;
• a hydrogen atom;
• a (C1-C18)alkyl group;
• a (C2-C18)alkenyl group;
• a (C2-C13)alkynyl group;
• a (C6-C10)aryl group optionally substituted by a halogen atom, by an optionally halogenated (C1-C5)alkyl group or by an optionally halogenated (C1-C5)alkoxy group;
• or a mono- or bicyclic (C4-C12)heteroaryl group containing one or more O, N and/or S atoms, which is optionally substituted by a halogen atom, by an optionally halogenated (C1-C5)alkyl group or by an optionally halogenated (C1-C5)alkoxy group;
• R3 and R4 are, each independently, a hydrogen atom;
• a (C1-C18)alkyl group;
• a (C2-C18)alkenyl group;
• a (C2-C18)alkynyl group;
• a (C6-C10)aryl group optionally substituted by a halogen atom, by an optionally halogenated (C1-C5)alkyl group or by an optionally halogenated (C1-C5)alkoxy group;
• or a mono- or bicyclic (C4-C12)heteroaryl group containing one or more O, N and/or S atoms, which is optionally substituted by a halogen atom, by an optionally halogenated (C1-C5)alkyl group or by an optionally halogenated (C1-C5)alkoxy group;
• or
• R3 and R4 together form a (C2-C6)alkylene chain optionally substituted by a halogen atom or by optionally halogenated (C1-C5)alkoxy;
• R is a halogen atom;
• a cyano group;
• a nitro group;
• a carboxy group;
• an optionally halogenated (C1-C18)alkoxycarbonyl group;
• an Ra—CO—NH— or RaRbN—CO— group;
• an optionally halogenated (C1-C18)alkyl group;
• optionally halogenated (C1-C18)alkoxy;
• and (C6-C10)aryl, (C6-C10)aryl(C1-C5)alkyl, (C6-C10)aryloxy, (C3-C12)cycloalkyl, (C3-C12)cycloalkenyl, (C3-C12)cycloalkyloxy or (C3-C12)cycloalkenyloxy, in which the aryl, cycloalkyl or cycloalkenyl group is optionally substituted by a halogen atom, by optionally halogenated (C1-C5)alkyl or by an optionally halogenated (C1-C5)alkoxy;
• —OH;
• Ra and Rb are, each independently, an optionally halogenated (C1-C18)alkyl;
• a hydrogen atom;
• (C6-C10)aryl or (C6-C10)aryl(C1-C5)alkyl, in which the aryl group is optionally substituted by a halogen atom, by an optionally halogenated (C1-C5)alkyl group or by an optionally halogenated (C1-C5)alkoxy group);
• (C3-C12)cycloalkyl optionally substituted by a halogen atom, by an optionally halogenated C1-C5 alkyl group or by an optionally halogenated (C1-C5)alkoxy group;
• p is 0, 1, 2, 3 or 4;
• Z is:
• n is 1 or 2;
• R′ are, each independently, a hydrogen atom;
• a (C1-C5)alkyl group;
• a (C6-C10)aryl group optionally substituted by a halogen atom, by an optionally halogenated (C1-C5)alkyl group or by optionally halogenated (C1-C5)alkoxy;
• or a mono- or bicyclic (C4-C12)heteroaryl group containing one or more O, N and/or S atoms, which is optionally substituted by a halogen atom, by an optionally halogenated (C1-C5)alkyl group or by an optionally halogenated (C1-C5)alkoxy group;
• Y is —OH;
• (C1-C5)alkoxy;
• or —NRcRd;
• or glucomic acid
• Rc and Rd are, each independently, a hydrogen atom;
• (C1-C5)alkyl;
• (C3-C8)cycloalkyl optionally substituted by a halogen atom, by optionally halogenated (C1-C5)alkyl or by optionally halogenated (C1-C5)alkoxy;
• (C6-C10)aryl optionally substituted by a halogen atom, by optionally halogenated (C1-C5)alkyl or by optionally halogenated (C1-C5)alkoxy;
• wherein one, and one alone, of R1 and R2 is Z;
• or a pharmaceutically acceptable salt thereof with a acid or base, or an ester thereof with the proviso that X is not 0 when A is —(CH2)s—CR3R4—(CH2)t—, in which one of s and t has the value 0 and the other has the value 1, wherein an unsubstituted methylene is bonded to X.